Awaiting product image

Article: KEYNOTE-048 supports pembrolizumab alone or in combination with chemotherapy as standard first-line therapies for recurrent/metastatic head and neck cancer

€3.03

SKU: product-article-8218 Category:

Description

KEYNOTE-048 supports pembrolizumab alone or in combination with chemotherapy as standard first-line therapies for recurrent/metastatic head and neck cancer

Reviews

There are no reviews yet.

Be the first to review “Article: KEYNOTE-048 supports pembrolizumab alone or in combination with chemotherapy as standard first-line therapies for recurrent/metastatic head and neck cancer”

Related products